Somerville Kurt F Has $3.68 Million Stock Position in Novo Nordisk A/S $NVO

Somerville Kurt F grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 31.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 66,313 shares of the company’s stock after purchasing an additional 15,975 shares during the period. Somerville Kurt F’s holdings in Novo Nordisk A/S were worth $3,680,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of NVO. Beacon Financial Group raised its position in Novo Nordisk A/S by 4.3% during the 3rd quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock worth $239,000 after purchasing an additional 178 shares during the last quarter. Kavar Capital Partners Group LLC increased its stake in shares of Novo Nordisk A/S by 0.6% in the third quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock valued at $1,811,000 after buying an additional 200 shares during the period. SeaBridge Investment Advisors LLC raised its position in shares of Novo Nordisk A/S by 5.7% during the third quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock worth $207,000 after acquiring an additional 200 shares during the last quarter. Joel Isaacson & Co. LLC lifted its stake in shares of Novo Nordisk A/S by 1.0% in the third quarter. Joel Isaacson & Co. LLC now owns 21,084 shares of the company’s stock worth $1,170,000 after acquiring an additional 200 shares during the period. Finally, Revolve Wealth Partners LLC boosted its holdings in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on NVO. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. CICC Research started coverage on Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 target price on the stock. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Citigroup started coverage on Novo Nordisk A/S in a report on Tuesday, January 27th. They set a “neutral” rating on the stock. Finally, Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Seven equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $56.07.

Novo Nordisk A/S Stock Down 1.9%

Novo Nordisk A/S stock traded down $0.91 during trading on Friday, hitting $47.55. 1,461,031 shares of the company were exchanged, compared to its average volume of 23,029,447. The company has a market capitalization of $212.29 billion, a P/E ratio of 13.60 and a beta of 0.67. The business’s 50 day moving average is $53.82 and its 200 day moving average is $53.21. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $93.80. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a $1.2751 dividend. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is presently 23.63%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.